223 related articles for article (PubMed ID: 12808293)
1. Antioxidative potential of fluvastatin via the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity.
Bandoh T; Sato EF; Mitani H; Nakashima A; Hoshi K; Inoue M
Biol Pharm Bull; 2003 Jun; 26(6):818-22. PubMed ID: 12808293
[TBL] [Abstract][Full Text] [Related]
2. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes.
Yamamoto A; Hoshi K; Ichihara K
Eur J Pharmacol; 1998 Nov; 361(1):143-9. PubMed ID: 9851551
[TBL] [Abstract][Full Text] [Related]
3. Antioxidative effects of fluvastatin and its metabolites against oxidative DNA damage in mammalian cultured cells.
Imaeda A; Tanigawa T; Aoki T; Kondo Y; Nakamura N; Yoshikawa T
Free Radic Res; 2001 Dec; 35(6):789-801. PubMed ID: 11811530
[TBL] [Abstract][Full Text] [Related]
4. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action.
Sumi D; Hayashi T; Thakur NK; Jayachandran M; Asai Y; Kano H; Matsui H; Iguchi A
Atherosclerosis; 2001 Apr; 155(2):347-57. PubMed ID: 11254905
[TBL] [Abstract][Full Text] [Related]
5. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits.
Rikitake Y; Kawashima S; Takeshita S; Yamashita T; Azumi H; Yasuhara M; Nishi H; Inoue N; Yokoyama M
Atherosclerosis; 2001 Jan; 154(1):87-96. PubMed ID: 11137086
[TBL] [Abstract][Full Text] [Related]
6. EPR studies on hydroxyl radical-scavenging activities of pravastatin and fluvastatin.
Vandjelovic N; Zhu H; Misra HP; Zimmerman RP; Jia Z; Li Y
Mol Cell Biochem; 2012 May; 364(1-2):71-7. PubMed ID: 22207075
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of fluvastatin on ileal ulcer formation in rats induced by nonsteroidal antiinflammatory drug.
Hagiwara M; Kataoka K; Arimochi H; Kuwahara T; Nakayama H; Ohnishi Y
World J Gastroenterol; 2005 Feb; 11(7):1040-3. PubMed ID: 15742411
[TBL] [Abstract][Full Text] [Related]
8. Antioxidative effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on peroxidation of phospholipid liposomes.
Yamamoto A; Ichihara K; Hoshi K
J Pharm Pharmacol; 2001 Feb; 53(2):227-32. PubMed ID: 11273020
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cholesterol synthesis ex vivo and in vivo by fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Yamamoto A; Itoh S; Hoshi K; Ichihara K
Experientia; 1995 Mar; 51(3):223-6. PubMed ID: 7698284
[TBL] [Abstract][Full Text] [Related]
10. [Antioxidative effects of fluvastatin, and its major metabolites].
Nakashima A; Ohtawa M; Masuda N; Morikawa H; Bando T
Yakugaku Zasshi; 1999 Jan; 119(1):93-9. PubMed ID: 9922713
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of fluvastatin and its metabolites on hydrogen peroxide-induced oxidative destruction of hemin and low-density lipoprotein.
Suzumura K; Tanaka K; Yasuhara M; Narita H
Biol Pharm Bull; 2000 Jul; 23(7):873-8. PubMed ID: 10919369
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro.
Suzumura K; Yasuhara M; Tanaka K; Suzuki T
Biochem Pharmacol; 1999 Mar; 57(6):697-703. PubMed ID: 10037456
[TBL] [Abstract][Full Text] [Related]
13. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.
Corsini A; Mazzotti M; Raiteri M; Soma MR; Gabbiani G; Fumagalli R; Paoletti R
Atherosclerosis; 1993 Jun; 101(1):117-25. PubMed ID: 8216498
[TBL] [Abstract][Full Text] [Related]
14. Direct effects of statins on the vascular wall.
Corsini A; Pazzucconi F; Arnaboldi L; Pfister P; Fumagalli R; Paoletti R; Sirtori CR
J Cardiovasc Pharmacol; 1998 May; 31(5):773-8. PubMed ID: 9593078
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery.
Bandoh T; Mitani H; Niihashi M; Kusumi Y; Ishikawa J; Kimura M; Totsuka T; Sakurai I; Hayashi S
Eur J Pharmacol; 1996 Nov; 315(1):37-42. PubMed ID: 8960862
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes.
Takahashi HK; Mori S; Iwagaki H; Yoshino T; Tanaka N; Weitz-Schmidt G; Nishibori M
J Leukoc Biol; 2005 Mar; 77(3):400-7. PubMed ID: 15618295
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits.
Mitani H; Bandoh T; Ishikawa J; Kimura M; Totsuka T; Hayashi S
Br J Pharmacol; 1996 Nov; 119(6):1269-75. PubMed ID: 8937733
[TBL] [Abstract][Full Text] [Related]
18. An in vitro study of the hydroxyl radical scavenging property of fluvastatin, and HMG-CoA reductase inhibitor.
Suzumura K; Yasuhara M; Tanaka K; Odawara A; Narita H; Suzuki T
Chem Pharm Bull (Tokyo); 1999 Jul; 47(7):1010-2. PubMed ID: 10434403
[TBL] [Abstract][Full Text] [Related]
19. Preservation of endothelial function by the HMG-CoA reductase inhibitor fluvastatin through its lipid-lowering independent antioxidant properties in atherosclerotic rabbits.
Mitani H; Egashira K; Ohashi N; Yoshikawa M; Niwa S; Nonomura K; Nakashima A; Kimura M
Pharmacology; 2003 Jul; 68(3):121-30. PubMed ID: 12784083
[TBL] [Abstract][Full Text] [Related]
20. Effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on nitric oxide-induced hydroxyl radical generation in the rat heart.
Obata T; Ebihara A; Yamanaka Y
Biochim Biophys Acta; 2001 Apr; 1536(1):55-63. PubMed ID: 11335104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
